Healthcare
AB Science S.A.(ABSCF)
Live Price
Offline$1.12
+0.00% today
Window Change
+0.00%
Window
May 29, 2026 โ Jun 18, 2026
- Market Cap
- $70.00M
- Revenue Growth
- +10.5%
- EPS Growth
- +37.5%
- Dividend Yield
- 0.0%
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 15 bars ยท May 29, 2026 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
AB Science S.A. (ABSCF) is a Healthcare stock with a market cap of $70.00M and listed on OTC. The stock last traded around $1.12 and up 0.0% across the available one-year price window (May 29, 2026 โ Jun 18, 2026). Baseline metrics include revenue growth of +10.5%, EPS growth of +37.5%, a dividend yield of 0.0%. What stands out right now is revenue +10.5%, EPS +37.5%, free cash flow +102.1% with operating margin -509.2% and ROIC -66.0%. Valuation already assumes a fairly strong business story at price/sales 64.4. Stock Foundry combines ABSCF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+10.5% vs +7.6% peer median
Operating Margin
Below sector median
-509.2% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report was closer to in-line
2026 was reported on May 13, 2026 with revenue ahead of estimates by 0.0%.
The operating story is still moving forward
Revenue is running at +10.5% and EPS at +37.5%, with operating margin around -509.2%.
The next real check-in already has a date
The next earnings event is scheduled for Sep 25, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Benchmark Edge
ABSCF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
ABSCF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
ABSCF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ABSCF and SPY.
Company Overview
AB Science S.A.
Other OTC
AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases, as well as in Phase II clinical trial to treat Covid-19. The company also develops AB8939, synthetic microtubule destabilizer for the treatment of acute myeloid leukemia; and AB20001, which is in Phase 2 clinical trial to evaluate the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients with moderate and severe COVID-19. It markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.
- Leadership
- Alain Moussy
- IPO Date
- Sep 9, 2011
- Employees
- 40
- Street Address
- 3, Avenue George V
- Mailing
- Paris, 75008
- Region
- Paris, FR
- Reporting Currency
- USD
- Investor Line
- 33 1 47 20 00 14
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 64.4
- Price/Book
- โ
Growth
- Revenue
- +10.5%
- EPS
- +37.5%
- Free Cash Flow
- +102.1%
Profitability
- Gross Margin
- 110.1%
- Operating Margin
- -509.2%
- Net Margin
- -831.5%
- ROE
- 33.4%
- ROIC
- -66.0%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.67
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.